Amylyx Pharmaceuticals, Inc.
AMLXNASDAQHealthcare● Active
$12.66
$-0.66(-4.93%)
Market Cap$1.1B
P/E Ratio—
52W High$18.605
52W Low$4.76
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AMLX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.37
Est. -$0.34 · -8.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
AMLX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.36 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.34 | -$0.37 | -8.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 3, 2026 | -$0.31 | -$0.30 | +3.2% | — | $-0.00B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.43 | -$0.37 | +13.9% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.44 | -$0.46 | -4.5% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.45 | -$0.42 | +6.7% | — | — | — |
| ▼ Q1 FY2025 | Mar 4, 2025 | -$0.49 | -$0.55 | -12.2% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.47 | -$0.53 | -12.8% | $0.00B | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.37
EPS Est.
-$0.34
EPS Surpr.
-8.8%
Revenue
—
Q1 FY2026
Mar 3, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.31
EPS Surpr.
+3.2%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.37
EPS Est.
-$0.43
EPS Surpr.
+13.9%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.44
EPS Surpr.
-4.5%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.42
EPS Est.
-$0.45
EPS Surpr.
+6.7%
Revenue
—
Q1 FY2025
Mar 4, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.49
EPS Surpr.
-12.2%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.53
EPS Est.
-$0.47
EPS Surpr.
-12.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q3 FY2026 | $-0.37 | $-0.34 | $-0.31 | 5 |
| Q2 FY2026 | $-0.40 | $-0.35 | $-0.32 | 6 |
| Q1 FY2026 | $-0.41 | $-0.34 | $-0.28 | 5 |
| Q4 FY2025 | $-0.43 | $-0.35 | $-0.16 | 7 |
| Q3 FY2025 | $-0.49 | $-0.44 | $-0.40 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.0B | $-0.0B | $-0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 10 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $-0.0B | $-0.0B | $-0.0B | 4 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -8.8% | $16.06 | $15.20 | -5.35% |
| ▲ Q1 FY2026 | Mar 3, 2026 | +3.2% | $15.30 | $14.11 | -7.78% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +13.9% | $13.24 | $12.46 | -5.89% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -4.5% | $8.19 | $7.84 | -4.27% |
| ▲ Q2 FY2025 | May 8, 2025 | +6.7% | $4.87 | $4.58 | -5.95% |
| ▼ Q1 FY2025 | Mar 4, 2025 | -12.2% | $3.00 | $3.01 | +0.33% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -12.8% | $6.22 | $6.54 | +5.14% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -92.1% | $1.88 | $1.80 | -4.26% |
Q2 FY2026-5.35%
Report Date
May 7, 2026
EPS Beat/Miss
-8.8%
Price Before
$16.06
Price After
$15.20
Q1 FY2026-7.78%
Report Date
Mar 3, 2026
EPS Beat/Miss
+3.2%
Price Before
$15.30
Price After
$14.11
Q4 FY2025-5.89%
Report Date
Nov 6, 2025
EPS Beat/Miss
+13.9%
Price Before
$13.24
Price After
$12.46
Q3 FY2025-4.27%
Report Date
Aug 7, 2025
EPS Beat/Miss
-4.5%
Price Before
$8.19
Price After
$7.84
Q2 FY2025-5.95%
Report Date
May 8, 2025
EPS Beat/Miss
+6.7%
Price Before
$4.87
Price After
$4.58
Q1 FY2025+0.33%
Report Date
Mar 4, 2025
EPS Beat/Miss
-12.2%
Price Before
$3.00
Price After
$3.01
Q4 FY2024+5.14%
Report Date
Nov 7, 2024
EPS Beat/Miss
-12.8%
Price Before
$6.22
Price After
$6.54
Q3 FY2024-4.26%
Report Date
Aug 8, 2024
EPS Beat/Miss
-92.1%
Price Before
$1.88
Price After
$1.80
Avg Beat Reaction-6.54%
Avg Miss Reaction-1.68%
Beat Rate3 / 8 quarters
Largest Move-7.78% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AMLX ends December
Amylyx Pharmaceuticals, Inc. (AMLX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.37 — missing the analyst consensus of $-0.34 by -8.8%. The next AMLX earnings date is expected around September 1, 2026.
Each quarter, investors track AMLX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AMLX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AMLX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AMLX earnings · 5 questionsAmylyx Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. AMLX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AMLX historically reports after market close (AMC).
AMLX earnings datewhen is AMLX earningsAMLX next earnings datewhen does AMLX report earningsAMLX earnings calendar
▸ Source: FMP · Amylyx Pharmaceuticals, Inc. SEC filings · US GAAP · Amylyx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026